Pathfinder Cell Therapy Stock Performance
| PFND Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pathfinder Cell are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pathfinder Cell Therapy has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Pathfinder Cell is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 44 K | |
| Free Cash Flow | -963 K |
Pathfinder |
Pathfinder Cell Relative Risk vs. Return Landscape
If you would invest 0.01 in Pathfinder Cell Therapy on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Pathfinder Cell Therapy or generate 0.0% return on investment over 90 days. Pathfinder Cell Therapy is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Pathfinder, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pathfinder Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pathfinder Cell's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pathfinder Cell Therapy, and traders can use it to determine the average amount a Pathfinder Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PFND |
Based on monthly moving average Pathfinder Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pathfinder Cell by adding Pathfinder Cell to a well-diversified portfolio.
Pathfinder Cell Fundamentals Growth
Pathfinder Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pathfinder Cell, and Pathfinder Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pathfinder Pink Sheet performance.
| Return On Asset | -8.89 | |||
| Current Valuation | 7.41 M | |||
| Shares Outstanding | 667.16 M | |||
| EBITDA | (1.67 M) | |||
| Cash And Equivalents | 4 K | |||
| Total Debt | 5.41 M | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (963 K) | |||
| Total Asset | 106 K | |||
| Retained Earnings | (19.23 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 6.77 M | |||
About Pathfinder Cell Performance
By analyzing Pathfinder Cell's fundamental ratios, stakeholders can gain valuable insights into Pathfinder Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pathfinder Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pathfinder Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. PATHFINDER CELL operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 1 people.Things to note about Pathfinder Cell Therapy performance evaluation
Checking the ongoing alerts about Pathfinder Cell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pathfinder Cell Therapy help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pathfinder Cell generated a negative expected return over the last 90 days | |
| Pathfinder Cell has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (1.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pathfinder Cell Therapy currently holds about 4 K in cash with (963 K) of positive cash flow from operations. |
- Analyzing Pathfinder Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pathfinder Cell's stock is overvalued or undervalued compared to its peers.
- Examining Pathfinder Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pathfinder Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pathfinder Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pathfinder Cell's pink sheet. These opinions can provide insight into Pathfinder Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pathfinder Pink Sheet analysis
When running Pathfinder Cell's price analysis, check to measure Pathfinder Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pathfinder Cell is operating at the current time. Most of Pathfinder Cell's value examination focuses on studying past and present price action to predict the probability of Pathfinder Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pathfinder Cell's price. Additionally, you may evaluate how the addition of Pathfinder Cell to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |